|
|
 |
|
Viewing report
|
|
|
|
Huntingtons Disease Therapeutics - Global Strategic Business Report
Global Industry Analysts, Inc., April 2010, Pages: 311
This report analyzes the Global market for Huntington’s Disease Therapeutics in US$ Million. Annual estimates and forecasts are provided for the period 2009 through 2015. The report profiles 37 companies including Alnylam Pharmaceuticals, Inc., Amarin Corporation, Plc, Avicena Group, Inc., Biovail Corporation, Ceregene, Inc., Cortex Pharmaceuticals, Inc., H. Lundbeck A/S, Intellect Neurosciences Incorporation, Medivation, Inc., NeuroSearch A/S, Prana Biotechnology Limited, Raptor Pharmaceuticals Corp., Targeted Genetics Corporation, Trophos SA, and Vertex Pharmaceuticals Incorporated. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks.
For information on site licence pricing please click on Enquire before buying
Customers who bought this item also bought
Stem Cell Approaches in Neurology and Psychiatry 2010
Lou Gehrigs Disease - Global Strategic Business Report
Dealmaking and Industry Outlook: Neurological Disease
Alzheimers and Parkinsons Disease - Global Strategic Business Report
The Neurodevice 2012 Report: Neuroprosthetics, Neuromodulation, Neurosurgery, Neurovascular Intervention and Neurosoftware
Inflammatory Bowel Disease Therapeutics - Global Strategic Business Report
Product Profiles: Depression - Next generation vies for second-line patients
Endpoints-Clinical Trials in Orphan Diseases - Highest Number of Terminated Trials Focused on Mulitiple Myeloma
Tinea Pedis (Athletes Foot) - Global Strategic Business Report
Parkinson's Disease Biomarkers: Vital Tools for Neuroprotectants
|
|
|
|
